TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Syntara Limited ( (AU:SNT) ) has shared an update.
Syntara Limited announced a webinar featuring key opinion leader Professor Ardeshir Bayat to discuss the treatment landscape for skin scarring and provide updates on their drug SNT-9465. SNT-9465, a topical anti-fibrotic drug, is currently in Phase 1 clinical trials and aims to address the unmet need for effective treatments for hypertrophic scars, potentially becoming the first approved pharmacological treatment in this area.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Syntara Limited stock, see the AU:SNT Stock Forecast page.
More about Syntara Limited
Syntara Limited is a clinical-stage drug development company specializing in extracellular matrix dysfunction. They leverage expertise in amine oxidase chemistry to develop novel medicines for blood cancers and conditions related to inflammation and fibrosis. Their lead candidate, amsulostat, targets myelofibrosis, and they are advancing other candidates for various fibrotic and inflammatory diseases.
Average Trading Volume: 2,536,417
Technical Sentiment Signal: Sell
Current Market Cap: A$47.34M
Find detailed analytics on SNT stock on TipRanks’ Stock Analysis page.